Contributions
Abstract: EP1564
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Serum neurofilament light chain (sNfL) has been proposed as a promising biomarker for treatment response in relapsing-remitting multiple sclerosis (RRMS) patients. We previously reported in a small cohort i) that sNfL was strongly associated with gadolinium-enhancing lesions and T2 lesion volume in patients with very early MS, ii) that higher baseline sNfL levels at diagnosis predicted brain atrophy levels after 24 months, and iii) that sNfL was reduced under baseline therapy (Siller et al., Mult Scler, 2018). However, it is currently unclear whether each individual patient's levels should be compared longitudinally or whether an absolute threshold can be defined for sufficient treatment control.
Objectives: To evaluate whether sNfL levels differ in relapsing-remitting patients with clinical and radiological response to treatment under lower and higher efficacy drugs.
Methods: From a cohort of 927 RRMS patients, we selected patients with no evidence of disease activity (NEDA-3) at time of blood withdrawal under different disease-modifying therapies (DMTs; interferons, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab (n = 50-80 patients per DMT group)). sNfL levels were determined using single molecule array technology.
Results: sNfL levels do not vary significantly between RRMS patients fulfilling NEDA-3 criteria receiving interferon (median 3,26 pg/ml [1,07 - 8,84]), glatiramer acetate (median 3,52 pg/ml [0,78 - 12,77]), dimethyl fumarate (median 2,59 pg/ml [0,46 - 14,6]), fingolimod (median 3,4 pg/ml [1,45 - 10]) or natalizumab treatment (median 3,24 pg/ml [1,08 - 7,57]). Patients were divided into quartiles according to their sNfL levels; data will be presented regarding whether high sNfL levels despite being clinically and radiologically stable indicate a risk for future disease exacerbation.
Conclusions: In a cohort of RRMS patients fulfilling NEDA-3 criteria, patients exhibit the same sNfL levels regardless of whether they receive baseline or escalation DMTs.
Disclosure: JP has nothing to disclose
FS has nothing to disclose
FL has nothing to disclose
FZ has nothing to disclose
SB has nothing to disclose
Abstract: EP1564
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Serum neurofilament light chain (sNfL) has been proposed as a promising biomarker for treatment response in relapsing-remitting multiple sclerosis (RRMS) patients. We previously reported in a small cohort i) that sNfL was strongly associated with gadolinium-enhancing lesions and T2 lesion volume in patients with very early MS, ii) that higher baseline sNfL levels at diagnosis predicted brain atrophy levels after 24 months, and iii) that sNfL was reduced under baseline therapy (Siller et al., Mult Scler, 2018). However, it is currently unclear whether each individual patient's levels should be compared longitudinally or whether an absolute threshold can be defined for sufficient treatment control.
Objectives: To evaluate whether sNfL levels differ in relapsing-remitting patients with clinical and radiological response to treatment under lower and higher efficacy drugs.
Methods: From a cohort of 927 RRMS patients, we selected patients with no evidence of disease activity (NEDA-3) at time of blood withdrawal under different disease-modifying therapies (DMTs; interferons, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab (n = 50-80 patients per DMT group)). sNfL levels were determined using single molecule array technology.
Results: sNfL levels do not vary significantly between RRMS patients fulfilling NEDA-3 criteria receiving interferon (median 3,26 pg/ml [1,07 - 8,84]), glatiramer acetate (median 3,52 pg/ml [0,78 - 12,77]), dimethyl fumarate (median 2,59 pg/ml [0,46 - 14,6]), fingolimod (median 3,4 pg/ml [1,45 - 10]) or natalizumab treatment (median 3,24 pg/ml [1,08 - 7,57]). Patients were divided into quartiles according to their sNfL levels; data will be presented regarding whether high sNfL levels despite being clinically and radiologically stable indicate a risk for future disease exacerbation.
Conclusions: In a cohort of RRMS patients fulfilling NEDA-3 criteria, patients exhibit the same sNfL levels regardless of whether they receive baseline or escalation DMTs.
Disclosure: JP has nothing to disclose
FS has nothing to disclose
FL has nothing to disclose
FZ has nothing to disclose
SB has nothing to disclose